ES2663698T3 - Procedimiento para la predicción del riesgo de progresión de tumores - Google Patents

Procedimiento para la predicción del riesgo de progresión de tumores Download PDF

Info

Publication number
ES2663698T3
ES2663698T3 ES09736808.8T ES09736808T ES2663698T3 ES 2663698 T3 ES2663698 T3 ES 2663698T3 ES 09736808 T ES09736808 T ES 09736808T ES 2663698 T3 ES2663698 T3 ES 2663698T3
Authority
ES
Spain
Prior art keywords
gene product
risk
predicting
cell proliferation
marker gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09736808.8T
Other languages
English (en)
Inventor
Peter Martin
Rüdiger Ridder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ventana Medical Systems Inc
Original Assignee
Ventana Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Medical Systems Inc filed Critical Ventana Medical Systems Inc
Application granted granted Critical
Publication of ES2663698T3 publication Critical patent/ES2663698T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Un procedimiento para predecir la posibilidad de crecimiento invasor y/o el riesgo de progresar a un cáncer de grado alto de tumores que comprende determinar en inmunohistoquímica o inmunocitoquímica la presencia simultánea de sobreexpresión del producto génico inhibidor de cinasas dependientes de ciclinas p16INK4a y la expresión de al menos un producto génico marcador de la proliferación celular en al menos una célula individual; en el que la presencia simultánea de sobreexpresión del producto génico inhibidor de cinasas dependientes de ciclinas p16INK4a y la expresión de al menos un producto génico marcador de la proliferación celular en al menos una célula individual es indicativa de una posibilidad de crecimiento invasor y un riesgo elevado de progresar a un cáncer de grado alto, y en el que el producto génico marcador de la proliferación celular se selecciona del grupo que consiste en Ki67, Ki-S2, MCM2, MCM5 y topoisomerasa 2 alfa.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11

Claims (1)

  1. imagen1
ES09736808.8T 2008-09-04 2009-09-04 Procedimiento para la predicción del riesgo de progresión de tumores Active ES2663698T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08105235 2008-09-04
EP08105235 2008-09-04
PCT/EP2009/006415 WO2010025928A1 (en) 2008-09-04 2009-09-04 Method for prediction of the progression risk of tumors

Publications (1)

Publication Number Publication Date
ES2663698T3 true ES2663698T3 (es) 2018-04-16

Family

ID=41395909

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09736808.8T Active ES2663698T3 (es) 2008-09-04 2009-09-04 Procedimiento para la predicción del riesgo de progresión de tumores

Country Status (7)

Country Link
US (3) US8728745B2 (es)
EP (1) EP2356460B1 (es)
AU (1) AU2009289822B2 (es)
CA (2) CA3117744C (es)
DK (1) DK2356460T3 (es)
ES (1) ES2663698T3 (es)
WO (1) WO2010025928A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1369694A1 (en) 2002-04-09 2003-12-10 MTM Laboratories AG Method for discrimination of metaplasias from neoplastic or preneoplastic lesions
ATE261126T1 (de) 2002-08-01 2004-03-15 Mtm Lab Ag Verfahren für lösung-basierte diagnose
EP1422526A1 (en) 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
EP2468899B1 (en) 2006-01-05 2015-03-11 The Ohio State University Research Foundation MicroRNA-based methods for the diagnosis of stomach cancers
JP2009543862A (ja) * 2006-07-14 2009-12-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ガンのバイオマーカーおよびその使用方法
EP2610347B1 (en) * 2007-04-30 2015-04-15 The Ohio State University Research Foundation Methods of determining the prognosis of a subject with pancreatic cancer
CN103866008B (zh) 2007-08-03 2016-06-29 俄亥俄州立大学研究基金会 编码ncrna的超保守区域
US20100285471A1 (en) * 2007-10-11 2010-11-11 The Ohio State University Research Foundation Methods and Compositions for the Diagnosis and Treatment of Esphageal Adenocarcinomas
AU2012323924A1 (en) 2011-10-14 2014-05-29 The Ohio State University Methods and materials related to ovarian cancer
CN104619353A (zh) 2011-12-13 2015-05-13 俄亥俄州国家创新基金会 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移
AU2013209477B2 (en) 2012-01-20 2016-12-08 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
US11543411B2 (en) 2014-12-05 2023-01-03 Prelude Corporation DCIS recurrence and invasive breast cancer
EP3304082B1 (en) 2015-06-08 2020-05-13 Arquer Diagnostics Limited Methods for analysing a urine sample
ES2911415T3 (es) 2015-06-08 2022-05-19 Arquer Diagnostics Ltd Métodos y kits
WO2020056338A1 (en) 2018-09-14 2020-03-19 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
EP3816934A1 (en) * 2019-11-04 2021-05-05 Nathan Vinçon Method of, and computerized system for labeling an image of cells of a patient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962316A (en) 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
DE10063112A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Erhöhung der klinischen Spezifität bei der Detektion von Tumoren und ihren Vorstufen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
EP1369694A1 (en) 2002-04-09 2003-12-10 MTM Laboratories AG Method for discrimination of metaplasias from neoplastic or preneoplastic lesions
EP1507148B1 (en) * 2003-08-25 2005-02-23 MTM Laboratories AG Method for detecting carcinomas in a solubilized cervical body sample
ATE261126T1 (de) 2002-08-01 2004-03-15 Mtm Lab Ag Verfahren für lösung-basierte diagnose
EP1422526A1 (en) 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
EP1510820B1 (en) * 2003-08-25 2010-03-17 MTM Laboratories AG Method for detecting medically relevant conditions in a solubilized LBC sample

Also Published As

Publication number Publication date
US20110183333A1 (en) 2011-07-28
CA2735853C (en) 2021-08-31
DK2356460T3 (en) 2018-03-26
US8728745B2 (en) 2014-05-20
CA3117744C (en) 2022-07-19
AU2009289822A1 (en) 2010-03-11
CA2735853A1 (en) 2010-03-11
EP2356460B1 (en) 2018-01-24
US20230133528A1 (en) 2023-05-04
CA3117744A1 (en) 2010-03-11
EP2356460A1 (en) 2011-08-17
US20150099651A1 (en) 2015-04-09
WO2010025928A1 (en) 2010-03-11
AU2009289822B2 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
ES2663698T3 (es) Procedimiento para la predicción del riesgo de progresión de tumores
Kasajima et al. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours
HK1143190A1 (en) Gene expression markers of tumor resistance to her2 inhibitor treatment
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
BRPI0707040B8 (pt) Método in vitro de seleção de um composto, método in vitro de previsão da presença de câncer, método de determinação in vitro da eficiência de um tratamento anticancerígeno e uso de um composto
CL2009000040A1 (es) Uso del compuesto 2,2-dimetil-n-((s)-6-oxo-6,7-dihidro-5h-dibenzo[b,d]azepin-7-il)-n'-(2,2,3,3,3-pentafluor-propil)-malonamida para el tratamiento del cancer, en particular de tumores solidos, metodos de fabricacion y kit que lo contiene.
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
CL2007001624A1 (es) Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular.
BR112015009752A2 (pt) conjugados de anticorpo/fármaco e métodos de uso
GT200600394A (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis.
EA201270606A1 (ru) Новое противоопухолевое применение кабазитаксела
WO2006039582A3 (en) Compositions and methods for diagnosing and treating brain cancer and identifying neural stem cells
CL2008003200A1 (es) Compuestos derivados de tiazol, inhibidores de la proteina quinasas; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de vejiga, de mama y de rinon.
Zhou et al. Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer
WO2008094964A3 (en) Cancer therapy prognosis
WO2012154567A3 (en) Human invasion signature for prognosis of metastatic risk
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
Lai et al. DEPTOR expression negatively correlates with mTORC1 activity and tumor progression in colorectal cancer
BR112015012507A8 (pt) método in vitro de seleção de um indivíduo diagnosticado ou suspeito de ter câncer e uso de um inibidor de telomerase
WO2012109632A3 (en) Crown-like structures as a biomarker for cancer risk and cancer prognosis
UY36200A (es) Conjunto de biomarcadores específicos para diagnóstico no invasivo de cáncer de hígado
GÜLTEKİN et al. Metaplastic breast carcinoma: a heterogeneous disease
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
ES2482168T3 (es) Uso de opioides del grupo de la metadona para el tratamiento de pacientes con cáncer resistente
HK1126278A1 (en) Identification of non-small cell lung carcinoma (nsclc) tumors expressing pdgfr-alpha pdgfr(nsclc)